Paper - Review

DOI: 10.1186/s13073-020-0721-z

Abstract

⁉: growing numbers of (immune checkpoint blockade trials)
← with available omics data
❓: remains challenging
→ to evaluate → the robust of 1⃣ ICB response 2⃣ immune evasion mechanisms comprehensively

Integrated
→ 1⃣ large-scale omics data 2⃣ biomarkers ← on published ICB trials 3⃣ non-immunotherapy tumor profiles 4⃣ CRISPR screens

Processed → the omics data
→ for over 33K samples ← in 188 tumor cohorts
→ 1⃣ 998 tumor ← from 12 ICB clinical studies 2⃣ 8 CRISPR screens ← that identified (gene modulators) ← of the anti-cancer immune response

∴ The utility of public data reuse
← 1⃣ hypothesis generation 2⃣ biomarker optimization 3⃣ patient stratification

---